Terns Pharmaceuticals, Inc. (TERN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-16

Key Insights

The reporting person, Amy L. Burroughs, the Chief Executive Officer of Terns Pharmaceuticals, Inc., has made significant transactions in the company's stock, including acquiring 150,000 restricted stock units and exercising stock options to acquire an additional 68,749 shares.
Burroughs has also sold a portion of her shares, disposing of 68,749 shares in total, likely for liquidity or diversification purposes.
The transactions were made pursuant to a Rule 10b5-1 trading plan, which suggests a structured and planned approach to managing her equity position in the company.

Want the newest filings?

This analysis covers the filing from 2026-01-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-16

The reporting person, Andrew Gengos, acquired 68,750 shares of Terns Pharmaceuticals, Inc. (TERN) common stock in the form of restricted stock units (RSUs) on January 14, 2026. This indicates a positive sentiment from a key executive regarding the company's prospects.
Gengos also received a stock option to purchase 137,500 shares of TERN common stock, with a vesting schedule that aligns his interests with long-term shareholder value creation.
The insider transaction amounts are relatively small in the context of Gengos' overall beneficial ownership of 101,788 shares, suggesting this is likely a routine equity award rather than a significant change in his investment position.

Filed: 2026-01-16

The reporting person, Emil Kuriakose, who is the Chief Medical Officer of Terns Pharmaceuticals, Inc. (TERN), has acquired 56,250 shares of common stock in the form of Restricted Stock Units (RSUs). This suggests that the executive is increasing their ownership stake in the company.
Kuriakose has also been granted 112,500 stock options with an exercise price of $37.18, vesting over a 4-year period. This indicates that the company is incentivizing the executive with long-term equity-based compensation.
The timing of these transactions, which occurred on January 14, 2026, suggests that the company may have recently reached a significant milestone or development that led to this award of equity compensation to the Chief Medical Officer.

Other reports for Terns Pharmaceuticals, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.